Portage Biotech (NASDAQ:ALP) Insider Acquires $44,000.00 in Stock

Portage Biotech Inc. (NASDAQ:ALP) insider Fiorenzo Villani purchased 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was bought at an average cost of $4.40 per share, with a total value of $44,000.00. Following the acquisition, the insider owned 48,886 shares in the company, valued at $215,098.40. This represents a 25.72% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Fiorenzo Villani also recently made the following trade(s):

• On Wednesday, September 16th, Fiorenzo Villani acquired 4,265 shares of Portage Biotech stock. The shares were bought at an average price of $4.05 per share, with a total value of $17,273.25.
• On Tuesday, September 15th, Fiorenzo Villani acquired 7,900 shares of Portage Biotech stock. The shares were bought at an average cost of $4.15 per share, for a total transaction of $32,785.00.
• On Tuesday, September 15th, Fiorenzo Villani acquired 10,382 shares of Portage Biotech stock. The stock was purchased at an average price of $4.07 per share, for a total transaction of $42,254.74.
• On Monday, September 14th, Fiorenzo Villani acquired 2,000 shares of Portage Biotech stock. The shares were purchased at an average price of $4.16 per share, with a total value of $8,320.00.
• On Wednesday, September 9th, Fiorenzo Villani bought 7,000 shares of Portage Biotech stock. The stock was purchased at an average price of $5.07 per share, for a total transaction of $35,490.00.

Portage Biotech Price Performance

Shares of NASDAQ:ALP traded up $0.04 during trading on Wednesday, reaching $4.39. The stock had a trading volume of 138,531 shares, compared to its average volume of 229,382. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.31 and a current ratio of 0.31. Portage Biotech Inc. has a 1-year low of $3.20 and a 1-year high of $690.00. The stock has a market cap of $6.80 million, a PE ratio of -0.01 and a beta of 0.54. The business has a fifty day moving average price of $9.06 and a 200-day moving average price of $14.06.

Portage Biotech (NASDAQ:ALP) last announced its quarterly earnings data on Thursday, July 16th. The company reported $23.75 earnings per share for the quarter. The firm had revenue of $0.05 million during the quarter. On average, equities analysts forecast that Portage Biotech Inc. will post -14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ALP has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Portage Biotech in a research report on Friday, July 24th. HC Wainwright initiated coverage on shares of Portage Biotech in a report on Monday, August 17th. They issued a “neutral” rating and a $12.50 price objective for the company. Wall Street Zen raised shares of Portage Biotech to a “hold” rating in a research note on Saturday, September 12th. Finally, Zacks Research raised shares of Portage Biotech to a “hold” rating in a research note on Tuesday, August 18th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus price target of $12.50.

About Portage Biotech

Portage Biotech Inc is a clinical-stage biotechnology company focused on developing immuno-oncology treatments designed to stimulate the immune system to target and eliminate cancer cells. Its research has centered on therapies involving invariant natural killer T (iNKT) cells, a specialized immune-cell population that may help generate targeted antitumor responses.

The company’s pipeline has included investigational therapies intended for use in solid tumors, including approaches that combine immune-cell activation with mechanisms designed to improve the tumor microenvironment and enhance treatment response.